

## Nasopharyngeal Pneumococcal Colonization among Children after Pneumococcal Conjugate Vaccine Introduction

Manoochehr Karami<sup>1</sup>, \*Zeinab Berangi<sup>2</sup>, Younes Mohammadi<sup>3</sup>, Seyed Mohsen Zahraei<sup>4</sup>

<sup>1</sup>Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>2</sup>Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>3</sup>Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. <sup>4</sup>Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.

### Dear Editor-in-chief,

World Health Organization has recommended all countries to introduction of Pneumococcal Conjugate Vaccine (PCV) in routine immunization schedule, especially those countries with higher rate of mortality in children. However, Islamic Republic of Iran and more than 50 other countries including Algeria, Antigua and Barbuda, Belarus, Belize, Bhutan, Bosnia and Herzegovina, Brunei Darussalam, Cabo Verde, Chad, China, Comoros, Cook Islands, Croatia, Cuba, Czech Republic, Democratic People's Republic of Korea, Dominica, Egypt, Equatorial Guinea, Estonia, Gabon, Grenada, Guinea, Haiti, India, Jamaica, Jordan, Malaysia, Maldives, Malta, Montenegro, Nauru, Poland, Romania, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Serbia, Seychelles, Slovenia, Somalia, South Sudan, Sri Lanka, Syrian Arab Republic, Tajikistan, Thailand, The former Yugoslav Republic of Macedonia, Timor-Leste, Tonga, Tunisia, Turkmenistan, Tuvalu, Ukraine, Vanuatu, and Viet Nam have not introduced PCV till April 2016.

World Health Organization indicated that after PCV introduction, both targeted and non-targeted vaccination population were affected by direct and indirect effects of PCV immunization (1). Epidemiological profile of *Streptococcus pneumoniae* related diseases include meningitis, pneumonia, sepsis and the prevalence of nasopharyngeal carriage will be changed following PCV integration into targeted vaccine countries (2). Published literature reviews (3-6) revealed that transmission and prevalence of nasopharyngeal carriage of *Streptococcus pneumoniae* will be decreased because of direct and indirect effects of PCV. Moreover, PCV targeted countries may have experience only change in the prevalence of nasopharyngeal pneumococcal colonization for vaccine-covered serotypes (7). In conclusion, policy makers and public health authorities of non-targeted PCV vaccine countries are highly recommended to consider serotype distribution and replacement before and after vaccine introduction regarding the sustained administration of PCV.

**Key Words:** Carriage, Children, Pneumococcal Conjugate Vaccine, *Streptococcus pneumoniae*.

\*Please cite this article as: Karami M, Berangi Z, Mohammadi Y, Zahraei SM. Nasopharyngeal pneumococcal colonization among children after Pneumococcal Conjugate Vaccine introduction. Int J Pediatr 2017; 5(8): 5547-48. DOI: **10.22038/ijp.2017.24325.2052**

### \*Corresponding Author:

Zeinab Berangi, Fahmide St., Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran. Postcode: 65178-3-8736.

Email: z.berangi@yahoo.com

Received date: Jun.10, 2017; Accepted date: Jun 22, 2017

## 2- CONFLICT OF INTEREST

The author claimed no conflict of interest.

## 3- REFERENCES

1. World Health Organization. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination. WHO Press, Geneva, Switzerland, 2012.
2. Hosseini SM, Poorolajal J, Karami M, Ameri P. Prevalence of Nasopharyngeal Carriage of Streptococcus pneumonia in Iran: A Meta-Analysis. *J Res Health Sci.* 2015;15(3):141-6.
3. World Health Organization. Pneumococcal vaccines WHO position paper – 2012. *Wkly Epidemiol Rec.* 2012;87:129-244. .
4. Lehmann D, Willis J. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. *Clinical Infectious Diseases* 2010, 50(11):1477–86.
5. Karami M. Surveillance Systems for Nosocomial Infections: Methods and Challenges. *Infection Control and Hospital Epidemiology* 2016;37(2):237-8. doi: 10.1017/ice.2.
6. Karami M, Alikhani MY. Serotype Replacement and Nasopharyngeal Carriage Due to the Introduction of New Pneumococcal Conjugate Vaccine to National Routine Immunization. *Jundishapur journal of microbiology* 2015;8(10): e24807. doi: 10.5812/jjm.24807.
7. Zhou JY, Isaacson-Schmid M, Utterson EC, Todd EM, McFarland M, Sivapalan J, et al. Prevalence of nasopharyngeal pneumococcal colonization in children and antimicrobial susceptibility profiles of carriage isolates. *International Journal of Infectious Diseases.*39:50-2.